Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosuppression after bone marrow transplantation

Am J Ophthalmol. 1997 May;123(5):702-3. doi: 10.1016/s0002-9394(14)71090-6.

Abstract

Purpose: To report a case in which we treated cytomegalovirus retinitis using an intravitreal ganciclovir sustained-release device in a patient negative for the human immunodeficiency virus, with a history of myeloproliferative syndrome with myelofibrosis and profound immunosuppression after allogeneic bone marrow transplantation.

Methods: Case report. Review of medical records and fundus photographs.

Results: After the ganciclovir device was implanted, the cytomegalovirus retinitis did not progress, and visual acuity improved. We removed the device 9 months after implantation.

Conclusions: The ganciclovir sustained-release device may be useful for treating cytomegalovirus retinitis in patients without the acquired immunodeficiency syndrome who are profoundly immunosuppressed and fail conventional intravenous therapy. If immune suppression is of limited duration, the device can be removed.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Bone Marrow Transplantation / adverse effects*
  • Cytomegalovirus Retinitis / drug therapy*
  • Cytomegalovirus Retinitis / etiology
  • Drug Implants
  • Female
  • Fluorescein Angiography
  • Fundus Oculi
  • Ganciclovir / therapeutic use*
  • Humans
  • Immune Tolerance
  • Immunocompromised Host*
  • Middle Aged
  • Myeloproliferative Disorders / therapy

Substances

  • Antiviral Agents
  • Drug Implants
  • Ganciclovir